NCT03401112 - A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

January 26, 2018

Primary Completion Date

August 28, 2020

Study Completion Date

August 28, 2020

Conditions

Sickle Cell Disease

Interventions

DRUG

IMR-687

Oral administration of IMR-687 once daily with or without HU.

DRUG

Placebo

Oral administration of placebo once daily with or without HU.

Trial Locations (13)

Medical University of South Carolina, Charleston

Foundation for Sickle Cell Disease Research, Hollywood

University of Illinois, Chicago

Loretto Hospital, Chicago

Baylor Scott & White Health, Temple

UCSF Benioff Children's Hospital Oakland, Oakland

University of Connecticut Health Center, Farmington

Sandwell & West Birmingham Hospital, Birmingham

Bristol Haematology and Oncology Centre, Bristol

Royal London Hospital, London

University College London Hospital, London

Guy's Hospital, London

Oxford Cancer & Haematology Centre, The Churchill Hospital, Oxford